Amalgamated Bank trimmed its position in Steris PLC (NYSE:STE) by 0.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,500 shares of the medical equipment provider’s stock after selling 144 shares during the quarter. Amalgamated Bank’s holdings in Steris were worth $1,763,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently modified their holdings of STE. Oregon Public Employees Retirement Fund lifted its stake in shares of Steris by 10,585.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 3,572,743 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 3,539,306 shares during the last quarter. Federated Investors Inc. PA lifted its stake in shares of Steris by 2,546.2% in the third quarter. Federated Investors Inc. PA now owns 868,434 shares of the medical equipment provider’s stock worth $99,348,000 after buying an additional 835,616 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Steris by 10.3% in the fourth quarter. BlackRock Inc. now owns 8,549,361 shares of the medical equipment provider’s stock worth $913,498,000 after buying an additional 800,900 shares during the last quarter. Villere ST Denis J & Co. LLC acquired a new stake in shares of Steris in the fourth quarter worth $63,124,000. Finally, Millennium Management LLC lifted its stake in shares of Steris by 1,457.4% in the fourth quarter. Millennium Management LLC now owns 607,474 shares of the medical equipment provider’s stock worth $64,909,000 after buying an additional 568,469 shares during the last quarter. Institutional investors and hedge funds own 88.03% of the company’s stock.
A number of analysts have recently weighed in on STE shares. Stephens restated a “buy” rating and issued a $135.00 price objective on shares of Steris in a research note on Thursday, February 14th. JMP Securities restated a “buy” rating and issued a $135.00 price objective on shares of Steris in a research note on Thursday, February 14th. Finally, Zacks Investment Research upgraded shares of Steris from a “sell” rating to a “hold” rating in a research note on Thursday, March 28th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $138.20.
NYSE:STE traded up $0.56 during trading hours on Friday, hitting $128.66. 365,862 shares of the company traded hands, compared to its average volume of 384,633. The stock has a market cap of $10.84 billion, a P/E ratio of 31.00 and a beta of 1.08. Steris PLC has a twelve month low of $93.50 and a twelve month high of $129.53. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.56 and a quick ratio of 1.99.
Steris (NYSE:STE) last released its earnings results on Monday, February 11th. The medical equipment provider reported $1.26 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.26. The firm had revenue of $696.24 million during the quarter, compared to analysts’ expectations of $687.90 million. Steris had a net margin of 9.85% and a return on equity of 12.50%. As a group, equities research analysts anticipate that Steris PLC will post 4.79 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, March 21st. Investors of record on Wednesday, February 27th were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.06%. The ex-dividend date was Tuesday, February 26th. Steris’s payout ratio is currently 32.77%.
In other Steris news, VP John Adam Zangerle sold 3,000 shares of the business’s stock in a transaction on Friday, January 25th. The shares were sold at an average price of $115.00, for a total value of $345,000.00. Following the sale, the vice president now owns 33,796 shares of the company’s stock, valued at approximately $3,886,540. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Walter M. Rosebrough, Jr. sold 50,000 shares of the business’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $125.00, for a total transaction of $6,250,000.00. Following the completion of the sale, the chief executive officer now directly owns 98,895 shares in the company, valued at approximately $12,361,875. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 58,646 shares of company stock valued at $7,284,093. Corporate insiders own 2.38% of the company’s stock.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.